CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in…
0,840€
3,39%
Echtzeit-Aktienkurs Cytomx Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Cytomx Therapeutics Inc. Aktie
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in…
Form 8-K CytomX Therapeutics, For: Nov 16
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron
CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies....…
CytomX Therapeutics Shares Rally on Regeneron Pact
CytomX Therapeutics Shares Rally on Regeneron Pact...…
Regeneron, CytomX Set Cancer-Therapy Collaboration >REGN CTMX
Regeneron, CytomX Set Cancer-Therapy Collaboration >REGN CTMX...…
CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do…
CytomX GAAP EPS of -$0.35 misses by $0.05, revenue of $16.92M misses by $3.13M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- Advancing wholly owned, next-generation conditionally activated therapeuticsCX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 -...…
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is…
CytomX Therapeutics to Present at Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in…